Radnet Stock Price, News & Analysis

DeepHealth (Nasdaq: RDNT) unveiled an expanded portfolio of imaging informatics and clinical AI solutions at RSNA 2025 on November 30, 2025. The announcement highlights integrations across Diagnostic Suite, TechLive, Operations Suite and modality-specific Clinical AI suites (Breast, Thyroid, Neuro, Chest, Prostate) running on DeepHealth OS to unify imaging workflows, reporting and AI orchestration.

Notable disclosed impacts include 400+ scanners connected to TechLive, 42% fewer MR room closures, support for > 10 million mammograms annually, a Nature Health analysis showing 21% higher breast cancer detection in 579,000 women, deployment at > 200 sites for Thyroid Suite, and > 2,000 customers with 5,000+ radiologists using DeepHealth solutions.

RadNet (NASDAQ: RDNT) subsidiary DeepHealth announced Wichita Radiological Group selected DeepHealth’s Operations Suite™ to replace WRG’s legacy RIS under a five-year agreement to modernize operations across its multi-site network.

The cloud-native, AI-powered platform unifies scheduling, registration, billing, analytics and patient communication to streamline workflows, automate tasks, improve staff experience and strengthen patient-centered care coordination. WRG reads more than 500,000 studies annually and supports a Level I trauma center, a VA Medical Center and three outpatient imaging centers. DeepHealth will present at RSNA 2025 (Nov 30–Dec 4) with booth #1329 South Hall.

RadNet (NASDAQ: RDNT) and DeepHealth reported results from the ASSURE study, the largest U.S. real-world analysis of AI-driven breast cancer screening, published in Nature Health on Nov 17, 2025. The study evaluated >579,000 women across 109 community imaging sites and found the AI-powered workflow in RadNet’s Enhanced Breast Cancer Detection (EBCD) program produced a 21.6% increase in cancer detection rate vs state-of-the-art 3D mammography, a 15% increase in positive predictive value, and maintained recall rates within ACR guidelines. Benefits were consistent across populations, including >150,000 Black women and a 22.7% boost for women with dense breasts.

RadNet (NASDAQ:RDNT) DeepHealth and GE HealthCare announced an expanded strategic collaboration on Nov 12, 2025 to broaden AI-powered imaging across modalities and geographies. The plan extends a 2024 mammography partnership to a worldwide breast solution, integrates GE ultrasound with DeepHealth Thyroid Suite for automated nodule detection and reporting, and proposes combining DeepHealth TechLive™ remote scanning with GE ultrasound to enable remote supervision and simplify workflows.

RadNet cited up to 30% exam time reduction and > 94% acceptance of Thyroid AI reports on 4,070+ nodules as performance highlights. Both companies will present demonstrations at RSNA Nov 30–Dec 4, 2025.

RadNet (NASDAQ: RDNT) announced the acquisition of CIMAR UK on November 11, 2025, integrating CIMAR into RadNet’s DeepHealth digital health unit to advance AI-powered, connected imaging-based care across the UK and Europe.

CIMAR provides cloud-native image management across >50% of NHS trusts and 80% of UK private hospital groups; an existing DeepHealth–CIMAR partnership already connects DeepHealth’s AI lung solution to >90% of NHS Lung Cancer Screening Program sites. UK data show a shift to earlier detection (76% detected at earlier stages vs 29% historically).

RadNet (NASDAQ: RDNT) reported Q3 2025 Revenue $522.9M (+13.4% YoY) and Adjusted EBITDA $84.9M (+15.2% YoY), with margin expansion of 26 bps to 16.2%.

Digital Health Revenue rose 51.6% to $24.8M; Digital Health Adjusted EBITDA was $3.5M. Aggregate advanced imaging volumes increased 13.0% (same-center +9.9%).

Balance sheet: $804.7M cash and Net Debt to Adjusted EBITDA ~1.0x. Company raised full-year 2025 guidance: Imaging Center revenue now $1,900–$1,930M, Imaging Center Adjusted EBITDA $276–$284M, Digital Health revenue $85–$95M.

RadNet (NASDAQ: RDNT) acquired the assets of Alpha RT to expand DeepHealth’s remote-imaging capabilities, combining Alpha RT’s staffing, training and AI safety monitoring with DeepHealth’s FDA-cleared TechLive™ remote scanning technology.

The combined portfolio supports remote MR, CT, PET and ultrasound scanning from an integrated command center, offers AI-driven MRI safety alerts, vendor-agnostic remote MRI technologist staffing, an MRI Tech Aide Certification program, and intelligent scheduling. Pilot metrics cited: a 0.06% recall rate on remote scans and a 42% reduction in MRI room closures.

RadNet (NASDAQ: RDNT) announced its Investor Day agenda for Tuesday, November 11, 2025, to be held 9:00 a.m.–2:30 p.m. ET at Nasdaq MarketSite in New York City with a live webcast and archived replay available.

Titled “On the Leading Edge of Healthcare: Advancing Imaging Through Innovation and Technology,” the event includes opening remarks and a financial overview, clinical spotlights, digital health and services presentations, demonstrations of DeepHealth AI products (Breast Suite, Diagnostic Suite, TechLive™, Patient Engagement), and two Q&A sessions. In-person attendance is by invitation; investors may request consideration via rdnt@addo.com.

RadNet (NASDAQ: RDNT) will host an Investor Day at the Nasdaq MarketSite in New York City on Tuesday, November 11, 2025 from 9:00 a.m. to 2:30 p.m. ET. The event will include presentations by senior executives and physician leaders on strategic priorities, market opportunities, and the company’s innovation roadmap.

In-person attendance is by invitation and requires registration. A live webcast and replay, plus slide presentations, will be available via www.radnet.com/investor-day and the company’s Investor Relations page.